Safety and efficacy of moxonidine in mild to moderate hypertension.
OBJECTIVE
Moxonidine, a new imidazoline II receptor agonist was evaluated in patients with essential hypertension.


METHODS
After an informed consent, 16 patients with essential hypertension were recruited. After a wash out period, the patients received increasing doses of Moxonidine (maximum dose 0.6 mg) for four weeks to control the blood pressure.


RESULTS
The mean reduction in blood pressure (systolic/diastolic) was 17.6/14.5 mm Hg in supine position and 18.2/12.6 mm Hg in standing position. The significant side effect was observed only in one patient.


CONCLUSIONS
Moxonidine thus appears to be safe and effective antihypertensive drug in patients with essential hypertension.
Jain
S
S
Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh.
Malhotra
P
P
Kumari
S
S
Varma
S
S
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D004844:Epistaxis / Q000139:chemically induced; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index
D000959:Antihypertensive Agents; D007093:Imidazoles; C043482:moxonidine